Optimization of molecular targeted treatment effectiveness in patients with inflammatory bowel disease based on novel glycoprotein markers

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K15965
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Osaka University
• Principal Investigator: Amano Takahiro 大阪大学, 医学部附属病院, 医員 (80836908)
• Project Period (FY): 2022-04-01 – 2024-03-31
• Keywords: 炎症性腸疾患 / 治療選択 / バイオマーカー / 糖タンパク質 / Cytometric Bead Array

Outline of Final Research Achievements

We enrolled patients with inflammatory bowel diseases (IBD) who has begun treatment with molecular targeted therapies between January 2019 and March 2023 at Osaka University Hospital and affiliated facilities. Out of approximately 500 patients enrolled in the study, serum trough concentration, which are useful for predicting treatment effectiveness, were measured during induction phase in approximately 200 patients who stared infliximab, adalimumab or ustekinumab. We investigated factors associated to serum trough concentrations and treatment effectiveness during the induction phase, and found that serum leucine-rich alpha-2 glycoprotein was useful and one of the criteria for selecting molecular targeted treatment for patients with IBD.

Free Research Field

炎症性腸疾患

Academic Significance and Societal Importance of the Research Achievements

炎症性腸疾患(IBD)に対する治療として、生物学的製剤や低分子化合物といった分子標的治療薬の開発が進んでおり、近年その治療選択肢の幅は飛躍的に広がっている。一方で、その選択基準は明確ではなく、バイオマーカーを用いた治療効果予測アルゴリズムの開発と個々のIBD患者の病態に応じた最適な治療選択方法の探索が求められている。今回の研究では血清Leucine-rich alpha-2 glycoproteinがその選択基準の一つになることが明確になり、IBD患者におけるQOL改善及び医療費削減につながる重要な学術的・社会的意義を有する。